Track EMMA and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap$633.55K
Enterprise Value$29.26M
Revenue (TTM)$20.43M
Net Income (TTM)-$3.50M
Free Cash Flow (TTM)-$12.00K
Financial Health
Cash$1.52M
Net Debt$28.63M
Debt Ratio1.41
Debt to Equity-0.47
Interest Coverage0.61
Valuation (TTM)
Price to Sales0.03
Price to Earnings-0.18
EV to EBITDA40.47
Price to Book-0.01
Price to Free Cash Flow-52.8
Margins (TTM)
Gross Profit Margin94.70%
EBITDA Margin3.54%
Operating Income Margin0.09%
Net Income Margin-17.11%
Free Cash Flow Margin-0.06%
Returns (5Y Avg)
Return on Invested Capital41.02%
Return on Assets-4.29%
Return on Equity27.34%
Return on Total Capital41.02%
Return on Capital Employed13.52%
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue-6.05%
Diluted EPS15.88%
Total Debt-32.08%
Capital Expenditures-27.52%
Free Cash Flow1.83%
CAGR (3Y)
Revenue-6.86%
Diluted EPS6.90%
Total Debt-56.16%
Capital Expenditures-45.22%
Free Cash Flow-9.44%
CAGR (1Y)
Revenue-43.73%
Diluted EPS-3.98%
Total Debt0.90%
Capital Expenditures-29.41%
Free Cash Flow-100.00%
$0.01-$0.00|-0.87%
52W High$0.02
52W Low$0.01
50D SMA$0.01
200D SMA$0.01
Volume10.00K
Emmaus Life Sciences Inc
21250 Hawthorne Boulevard, Torrance, CA, United States, 90503
IPO
-
Employees
32
Industry
Biotechnology
Sector
Healthcare
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, such as leukemia, lymphoma, and solid tumor cancers. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
Insider Transactions
Quarterly buy vs. sell activity
No insider transactions data available for this period
Analyst Ratings
No coverage data
No analyst ratings data available